RESUMO
The mutation V617F of gene JAK2 is detected in 95% of patients with genuine polycythemia, in 50% of patients with essential thrombocytemia and idiopathic myelofibrosis. The mutation V617F can be applied as a molecular marker of response to treatment in patients with chronic myeloproliferative diseases associated with this mutation. The technique of quantitative evaluation of V617F (sensitivity up to 0.01%) using polymerase chain reaction is described. This method can be applied to assess the minimal residual disease in patients with chronic myeloproliferative diseases.
Assuntos
Doença Crônica , Janus Quinase 2/sangue , Mutação , Transtornos Mieloproliferativos/sangue , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Linhagem Celular , Criança , Estudos de Avaliação como Assunto , Humanos , Janus Quinase 2/genética , Pessoa de Meia-Idade , Transtornos Mieloproliferativos/genética , Policitemia/sangue , Policitemia/genética , Mielofibrose Primária/sangue , Mielofibrose Primária/genética , Trombocitemia Essencial/sangue , Trombocitemia Essencial/genéticaAssuntos
Cobre/uso terapêutico , Linfócitos/efeitos da radiação , Compostos Organometálicos/uso terapêutico , Lesões Experimentais por Radiação/prevenção & controle , Protetores contra Radiação/uso terapêutico , Animais , Fluorometria , Masculino , Lesões Experimentais por Radiação/sangue , Lesões Experimentais por Radiação/tratamento farmacológico , RatosRESUMO
In experiments with rats and mice irradiated with doses of 5 and 8.5 Gy respectively, the radioprotective properties of a coordination combination Co(III) with bioactive ligands have been investigated by the results of the hematological analysis, the indices of erythrocyte and leucocyte electric conductivity, average life, survival rate, and beta coefficient showing a probability of protecting the organism against fatal effect of ionizing radiation. The preparation has either therapeutic or protective action depending on the animal species and radiation dose.